GlassScriptPhysician profile
Rachel Vann
NPI 1801248349
$11,150.55
in general payments reported to CMS, 2019-2025
47 companies · $2,998 in 2025
The $2,998 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,708 · 2022: $1,517 · 2023: $2,470 · 2024: $2,459 · 2025: $2,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,836 · Education: $89.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,836.48 |
| Education | $89.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,794.84 | 2021-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $967.28 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $722.18 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $713.11 | 2021-2025 | Provenge |
| Pfizer INC. | $661.81 | 2021-2025 | |
| Astellas Pharma US INC | $617.70 | 2021-2025 | Xtandi, Myrbetriq |
| Myovant Sciences INC. | $552.92 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $523.44 | 2021-2025 | Prolaris |
| Urogen Pharma, INC. | $509.53 | 2023-2025 | Jelmyto |
| Boston Scientific Corporation | $422.22 | 2023-2025 | Rezum Generator, Spaceoar Vue System - 10ml, General - Erectile Dysfunction |
| C. R. Bard, INC. & Subsidiaries | $249.61 | 2024-2025 | Bard Urinary Drainage Bag, Magic3 Go Intermittent Urinary Catheter |
| Amgen INC. | $221.43 | 2021-2023 | Xgeva, Prolia |
| Medtronic, INC. | $198.00 | 2022-2024 | Interstim |
| Urovant Sciences INC | $175.12 | 2022 | |
| Progenics Pharmaceuticals, INC. | $164.33 | 2021-2025 | Pylarify |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $162.04 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $161.77 | 2021-2025 | |
| Tempus Ai, INC | $161.54 | 2024-2025 | Xt Cdx |
| Kowa Pharmaceuticals America, INC. | $160.23 | 2022 | |
| Blue Earth Diagnostics | $154.83 | 2021-2024 | |
| Clarus Therapeutics INC. | $153.02 | 2021 | |
| Antares Pharma, INC. | $150.07 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Teleflex LLC | $142.58 | 2021 | |
| Merck Sharp & Dohme LLC | $141.90 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Sun Pharmaceutical Industries INC. | $136.43 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $132.29 | 2022-2024 | |
| Allergan, INC. | $124.99 | 2022 | |
| Endo USA, INC. | $111.66 | 2024-2025 | Xiaflex, Aveed |
| Tolmar, INC. | $110.17 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $108.78 | 2021-2024 | Xiaflex, Aveed |
| Accord Healthcare, INC. | $82.50 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $64.40 | 2024-2025 | |
| Inspire Medical Systems, INC. | $38.78 | 2024 | Inspire |
| Tolmar Pharmaceuticals, INC. | $38.48 | 2022 | |
| Olympus America INC. | $37.65 | 2025 | Itind System |
| E.R. Squibb & Sons, L.L.C. | $31.43 | 2022-2023 | Opdivo |
| Telix Pharmaceuticals | $30.48 | 2025 | Illuccix |
| Coloplast Corp | $30.15 | 2022-2025 | |
| 180 Medical, INC. | $28.36 | 2023 | Gentlecath |
| Calyxo, INC. | $28.32 | 2025 | Cvac Aspiration System |
| Sandoz INC. | $23.14 | 2025 | Jubbonti |
| Immunitybio, INC. | $22.38 | 2025 | |
| Caris Mpi, INC. | $21.53 | 2025 | Mi Cancer Seek |
| Verity Pharmaceuticals INC. | $20.14 | 2025 | Trelstar |
| Dentsply Ih Ab | $19.66 | 2024 | Lofric |
| Azurity Pharmaceuticals, INC. | $13.88 | 2025 | Azmiro |
| Halozyme INC | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Vann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.